Roy Buchanan

Stock Analyst at JMP Securities

(0.52)
# 2519
Out of 5,378 analysts
73
Total ratings
Success rate
Average return
18 Stocks
Name Action PT Current % Upside Ratings Updated
PYPD PolyPid
Maintains: Market Outperform
16 14
3.67 281.47% 2 Jun 17, 2025
ENTA Enanta Pharma
Maintains: Market Outperform
23 24
7.08 238.98% 13 Jun 3, 2025
CDTX Cidara Therapeutics
Reiterates: Market Outperform
47 47
44.83 4.84% 5 Jun 2, 2025
CVAC CureVac
Reiterates: Market Outperform
10 10
5.38 85.87% 9 May 28, 2025
DVAX Dynavax Technologies
Maintains: Market Outperform
33 31
9.73 218.6% 6 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
5 2
1.07 86.92% 9 May 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
18 18
1.94 827.84% 3 Mar 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Perform
n/a
n/a n/a 1 Feb 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
7 4
1.04 284.62% 3 Feb 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
23 14
0.68 1958.82% 1 Jan 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
33 33
6.11 440.1% 1 Jan 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
24 7
1.27 451.18% 2 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 5 Oct 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
4 5
3.42 46.2% 5 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 3 Jul 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
443 448
540.88 -17.17% 2 Mar 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
14 16
16.6 -3.61% 1 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Feb 16, 2023